We are live on ! Find out more
CRSP icon

CRISPR Therapeutics
CRSP

433 hedge funds and large institutions have $3.52B invested in CRISPR Therapeutics in 2025 Q2 according to their latest regulatory filings, with 101 funds opening new positions, 127 increasing their positions, 101 reducing their positions, and 60 closing their positions.

New
Increased
Maintained
Reduced
Closed

68% more first-time investments, than exits

New positions opened: 101 | Existing positions closed: 60

60% more capital invested

Capital invested by funds: $2.2B → $3.52B (+$1.32B)

31% more call options, than puts

Call options by funds: $244M | Put options by funds: $186M

26% more repeat investments, than reductions

Existing positions increased: 127 | Existing positions reduced: 101

9% more funds holding

Funds holding: 396 → 433 (+37)

8.4% more ownership

Funds ownership: 75.39% → 83.79% (+8.4%)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

Holders
433
Holders Change
+37
Holders Change %
+9.34%
% of All Funds
5.7%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
101
Increased
127
Reduced
101
Closed
60
Calls
$244M
Puts
$186M
Net Calls
+$58.2M
Net Calls Change
+$37.5M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$134M
2
OAG
Orbis Allan Gray
Bermuda
+$46.5M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$39.7M
4
State Street
State Street
Massachusetts
+$33.3M
5
UBS Group
UBS Group
Switzerland
+$29.9M

Top Sellers

Rank Fund Capital Flow
1
UBS AM
UBS AM
Illinois
-$38.2M
2
Morgan Stanley
Morgan Stanley
New York
-$30.5M
3
BBA
Baker Bros. Advisors
New York
-$22.3M
4
Millennium Management
Millennium Management
New York
-$19.9M
5
Capital International Investors
Capital International Investors
California
-$18.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
Creative Planning
151
Creative Planning
Kansas
$770K +$87.6K +2,263 +17%
TWP
152
Tyche Wealth Partners
Texas
$768K +$255K +6,600 +72%
ASN
153
Advisory Services Network
Georgia
$758K +$136K +3,509 +35%
SC
154
Scotia Capital
Ontario, Canada
$754K +$22K +569 +4%
WA
155
Waverly Advisors
Alabama
$749K +$5.53K +143 +0.9%
KAS
156
Kestra Advisory Services
Texas
$708K -$73.1K -1,888 -11%
IA
157
Inspire Advisors
Idaho
$704K +$38.7K +999 +7%
CIBC World Market
158
CIBC World Market
Ontario, Canada
$686K +$108K +2,785 +25%
MWM
159
Moran Wealth Management
Florida
$664K +$528K +13,654 New
Janney Montgomery Scott
160
Janney Montgomery Scott
Pennsylvania
$661K +$112K +2,882 +27%
BAM
161
Brave Asset Management
New Jersey
$658K +$314K +8,125 +150%
PI
162
PFG Investments
New York
$627K +$96.2K +2,487 +24%
EFM
163
E Fund Management
China
$621K -$34.2K -884 -6%
Federated Hermes
164
Federated Hermes
Pennsylvania
$614K +$488K +12,617 New
CGIM
165
Capital Group Investment Management
Singapore
$591K -$93.9K -2,427 -17%
Mariner
166
Mariner
Kansas
$581K +$462K +11,946 New
AWM
167
Axxcess Wealth Management
California
$562K +$48K +1,241 +12%
SRL
168
Scientech Research LLC
New Jersey
$557K +$443K +11,445 New
SEI Investments
169
SEI Investments
Pennsylvania
$555K +$442K +11,414 New
AF
170
Allworth Financial
California
$552K -$7.86K -203 -2%
AAS
171
Avantax Advisory Services
Texas
$541K +$18K +464 +4%
BCWM
172
Bartlett & Co Wealth Management
Ohio
$540K – – –
KPWS
173
Kestra Private Wealth Services
Texas
$529K -$430K -11,117 -51%
VIA
174
Virtus Investment Advisers
Connecticut
$524K +$111K +2,860 +36%
AWA
175
Arkadios Wealth Advisors
Georgia
$516K -$24.1K -623 -6%
5 6
7
8 9

CRSP Hedge Fund Activity: Q2 2025 in Review

433 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q2 2025, worth a combined $3.52B — up 60% from $2.2B a quarter earlier.

Buyers outnumbered sellers: 101 funds opened new CRSP positions and 60 closed out — a net gain of 41 holders — while 127 added to existing stakes and 101 trimmed.

The largest buyer was BlackRock, adding an estimated $134M. The largest seller was UBS AM, cutting an estimated $38.2M.

  • 433 institutional investors held CRISPR Therapeutics (CRSP) as of Q2 2025, up from 396 in Q1 2025.
  • Funds reported $3.52B of CRISPR Therapeutics stock for Q2 2025, up 60% quarter-over-quarter.
  • 101 funds opened new CRISPR Therapeutics positions in Q2 2025 and 60 closed out, a net change of +41 holders.
  • The largest CRISPR Therapeutics buyer in Q2 2025 was BlackRock, an estimated $134M added.
  • The largest CRISPR Therapeutics seller in Q2 2025 was UBS AM, an estimated $38.2M sold.

Based on aggregated 13F filings for Q2 2025.